As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says the kidney cancer drug’s additional indications in liver cancer and potentially other cancers will raise peak sales beyond €500 million.